Hearn P R, Reynolds C L, Johansen K, Woodhouse N J
Department of Biological Research, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Clin Endocrinol (Oxf). 1988 Feb;28(2):181-5. doi: 10.1111/j.1365-2265.1988.tb03654.x.
Two patients with Cushing's syndrome due to lung carcinoid tumours were given the long-acting somatostatin analogue SMS 201-995 (Sandostatin). One received a single 50 micrograms dose which produced a 50% reduction in circulating ACTH levels within 4 h. The other has been maintained in clinical and biochemical remission for 10 weeks on 100 micrograms tid. This is the first report of the successful use of SMS 201-995 in carcinoid-induced Cushing's syndrome, and suggests that this hormone analogue could be valuable in the long term medical management of such patients.